Accelerated Partial Breast Irradiation (APBI) Michael Zhang (MSIV), - - PowerPoint PPT Presentation

▶
accelerated partial breast irradiation apbi
SMART_READER_LITE
LIVE PREVIEW

Accelerated Partial Breast Irradiation (APBI) Michael Zhang (MSIV), - - PowerPoint PPT Presentation

Dec 06, 2023 350 likes •562 views

Accelerated Partial Breast Irradiation (APBI) Michael Zhang (MSIV), Matthew Spraker, MD, PhD (PGY3) Faculty Mentor: Janice Kim, MD University of Washington/Seattle Cancer Care Alliance Seattle, WA November 16, 2015 Case Presentation 62

slide-1
SLIDE 1

Accelerated Partial Breast Irradiation (APBI)

Michael Zhang (MSIV), Matthew Spraker, MD, PhD (PGY3) Faculty Mentor: Janice Kim, MD University of Washington/Seattle Cancer Care Alliance Seattle, WA

November 16, 2015

slide-2
SLIDE 2

Case Presentation

  • 62 year old female underwent annual bilateral

screening mammogram

– A new focal asymmetry in the left breast upper

  • uter quadrant was demonstrated
  • Patient is otherwise asymptomatic
slide-3
SLIDE 3

Patient History

  • Past Medical History

– Hyperlipidemia

  • Past Surgical History

– Tonsillectomy as a child – C-section in 1984

  • Medications

– Atorvastatin

  • No known drug allergies
slide-4
SLIDE 4

Patient History (con’t)

  • Gynecologic History

– G2P3, 28 years old at first pregnancy – Second pregnancy identical twins – Menarche at 13, natural menopause at 50 – OCP use from age 21-27, and hormone replacement therapy from age 52-54.

  • Social History

– Currently working full time as an engineer. – Never smoker, no current alcohol or drug use, or history of IV drug use. No prior XRT exposure. – Strong family support.

  • No known family history of malignancy
slide-5
SLIDE 5

Physical Exam

  • Vitals: HR 62, BP 117/75, RR 13, Temp 98.4F
  • General: Well-appearing female, relaxed, alert,

conversational.

  • Lymphatics: No palpable cervical, supraclavicular, or axillary

lymphadenopathy bilaterally.

  • CV: RRR, no murmurs, rubs, or gallops.
  • Resp: CTA B/L.
  • Breast: Breasts are symmetrical and appear to be D cup
  • breasts. There is no visible erythema, edema, nipple

inversion, or discharge. There are no palpable masses.

  • Neurologic: CN II-XII grossly intact, no focal neurologic

deficits otherwise noted, sensation grossly intact throughout, gait normal.

slide-6
SLIDE 6

Diagnostic Workup

  • Diagnostic left mammogram

– Confirms 13mm irregular mass in the left breast at 1

  • ’clock, mid-depth.
  • Targeted US of left breast

– Re-demonstrates 13mm solid mass in the left breast at 1

  • ’clock, 30mm from nipple.
  • US-guided core needle biopsy

– Invasive ductal carcinoma – Intermediate grade – ER/PR positive (Allred 8/8 for both), Her2/neu amplification negative by FISH analysis.

slide-7
SLIDE 7

Multidisciplinary Discussion

  • Patient was presented at the multidisciplinary

breast cancer tumor board.

  • Presented options for local treatment: simple

mastectomy, lumpectomy/SLNB + WBI, or lumpectomy/SLNB + accelerated partial breast irradiation (APBI).

  • The patient elected to undergo

lumpectomy/SLNB + APBI using Contura multi- lumen balloon catheter.

November 16, 2015

slide-8
SLIDE 8

Introduction to APBI

  • Whole breast irradiation (WBI)

– Standard of care after breast conservation surgery for early stage breast cancer.

  • APBI introduced with possible advantages over

WBI while providing equivalent LC in low risk patients

– Shortened treatment course

  • Typically 5-7 days vs 4-6 weeks

– Decreased radiation dose/toxicity

  • Reduced exposure to heart, lung, ribs.

November 16, 2015

slide-9
SLIDE 9

Which patients should be considered for APBI?

  • Must be candidates for breast-conserving therapy

– No prior radiotherapy – No history of collagen vascular diseases – Not pregnant

  • Consensus guidelines from ASTRO in 2009 put

patients into 3 classes

– Suitable – Cautionary – Unsuitable

November 16, 2015

slide-10
SLIDE 10

ASTRO consensus statement for APBI

Suitable (Pt meets all criteria) Cautionary (Pt meets any criteria) Unsuitable (Pt meets any criteria) Age ≥ 60 50-59 < 50 Tumor Size, T stage ≤ 2 cm, T1 2.1 – 3 cm, T0 or T2 > 3 cm, T3-T4 N stage, surgery pN0 (SNBx or ALND) pN1-3 or no nodal surgery Margins Negative (≤ 2 mm) Close (< 2 mm) Positive LVSI No Limited/focal Extensive ER status Positive Negative Centricity Unicentric Microscopic multi- centricity Present Histology Invasive ductal or favorable histology Invasive lobular EIC or Pure DCIS Not allowed ≤ 3 cm > 3 cm Associated LCIS Allowed Neoadjuvant Tx Not allowed Received

November 16, 2015

slide-11
SLIDE 11

ASTRO vs. ABS vs. ASBS

ASTRO “Suitable” (2009) ABS (2013) ASBS (2011) Age ≥ 60 ≥ 50 ≥ 45 (IDCA), ≥ 50 (DCIS) Tumor Size, T stage ≤ 2 cm, T1 ≤ 3 cm ≤ 3 cm N stage, surgery pN0 (SNBx or ALND) pN0 (SNBx or ALN level I/II) pN0 (SNBx) Margins Negative (≤ 2 mm) Negative microscopic Negative microscopic Centricity Unicentric, clinically unifocal Unifocal LVSI Not present Not present Histology Invasive ductal or favorable histo Any invasive Invasive ductal or DCIS

November 16, 2015

Comparison of criteria for approved group

slide-12
SLIDE 12

APBI Methodology

  • Multiple methods available

– Brachytherapy

  • Multi-catheter interstitial (High, Low, or Pulsed dose rates)
  • SAVI
  • Balloon catheterization (Mammosite, Contura)

– External beam

  • Electrons
  • 3D-CRT/IMRT
  • Protons

– Single-dose intraoperative radiotherapy (IORT)

  • Multi-catheter interstitial brachytherapy has longest

history, but currently data lacking to determine optimal method of delivering APBI.

November 16, 2015

slide-13
SLIDE 13

RTOG 95-17 - Phase II trial

  • APBI alone using multi-catheter interstitial brachytherapy

after lumpectomy in early-stage breast cancer.

  • 99 patients treated prospectively with HDR or LDR

brachytherapy.

– Eligibility: Stage I/II, unifocal, invasive non-lobular, negative margins, Tumor ≤3cm, Level I/II ALND with 0-3 positive nodes without ECE.

Tumor control (Arthur 2008 IJROBP)

November 16, 2015

Modality # pts tx Median f/u 5-year failure rates Survival rates

Ipsilat. br Contralat. br Regional Mastectomy free Disease free Overall

HDR

(34Gy, 10 BID

fxns in 5 days)

66 6.55 yrs 3% 2% 5% 88% 86% 92% LDR

(45Gy in 3.5-6

days)

33 7.09 yrs 6% 6% 0% 85% 88% 94%

slide-14
SLIDE 14

RTOG 95-17 - Phase II trial (cont’d)

  • Toxicity and cosmesis (Rabinovitch et al. 2014)

– Skin toxicity at 5 years (% of pts):

  • Grade 1-2 (78%), Grade 3 (13%), no G4
  • 54% - Catheter marks
  • 45% - Fibrosis
  • 45% - Telangiectasias
  • 37% - Dimpling or indentation
  • 15% - Symptomatic fat necrosis (1 req’d surgical excision, no pt req’d mastectomy)

– Patient-reported outcomes after 5 years (% of pts):

  • Breast asymmetry (73%), of which 77% reported a smaller treated breast
  • Excellent/good cosmesis (66%)
  • Satisfaction w/ treatment (75%)
  • Would choose same treatment again (95%)

November 16, 2015

slide-15
SLIDE 15

Treatment

  • Our patient underwent lumpectomy/SLNB with

Contura maintenance catheter placement intraop

– Invasive ductal carcinoma measuring 7mm – No associated DCIS – Surgical resection margins widely negative (>5mm for all margins) – ER+, PR+, Her2/neu amplification negative – SLNBx reviewed intraoperatively 0/2 LNs positive for disease

  • Contra balloon spacer replaced with Contura HDR

brachytherapy unit during CT simulation

slide-16
SLIDE 16

Treatment

  • CT simulation completed with brachytherapy

device in place. Pt is simulated on breast board with both arms up.

  • Maintenance catheter was removed and Contura

treatment catheter device placed with radio-

  • paque dye to visualize balloon and intraluminal

catheters for treatment planning.

  • Treatment device remains in place for 5 days.
  • Total dose of 34Gy delivered in BID fractions with

greater than 6 hours of intrafx interval.

slide-17
SLIDE 17

Treatment

November 16, 2015

Five catheter channels connected to HDR after-loader for treatment

slide-18
SLIDE 18

Treatment Set Up

November 16, 2015

Catheter aligned to tattoo to ensure daily rotational consistency.

slide-19
SLIDE 19

Fluoroscopic imaging to ensure set up performed prior to each daily fraction

Day 1 – Fluoroscopy set up Day 3 – Fluoroscopy set up

November 16, 2015

slide-20
SLIDE 20

References

  • American Society of Breast Surgeons, 2011, https://www.breastsurgeons.org/statements/PDF_Statements/APBI.pdf
  • Arthur, D.W., Winter, K., Kuske, R.R., Bolton, J., Rabinovitch, R., White, J., Hanson, W.F., Wilenzick, R., and McCormick, B.

(2008). A Phase II Trial of Brachytherapy Alone Following Lumpectomy for Select Breast Cancer: tumor control and survival

  • utcomes of RTOG 95-17. Int. J. Radiat. Oncol. Biol. Phys. 72, 467–473.
  • Kamrava, M., Kuske, R.R., Anderson, B., Chen, P., Hayes, J., Quiet, C., Wang, P.-C., Veruttipong, D., Snyder, M., and Jeffrey

Demanes, D. (2015). Outcomes of Breast Cancer Patients Treated with Accelerated Partial Breast Irradiation Via Multicatheter Interstitial Brachytherapy: The Pooled Registry of Multicatheter Interstitial Sites (PROMIS) Experience. Ann.

  • Surg. Oncol.
  • Rabinovitch, R., Winter, K., Kuske, R., Bolton, J., Arthur, D., Scroggins, T., Vicini, F., McCormick, B., and White, J. (2014). RTOG

95-17, a Phase II trial to evaluate brachytherapy as the sole method of radiation therapy for Stage I and II breast carcinoma-- year-5 toxicity and cosmesis. Brachytherapy 13, 17–22.

  • Shah, C., Vicini, F., Wazer, D.E., Arthur, D., and Patel, R.R. (2013). The American Brachytherapy Society consensus statement

for accelerated partial breast irradiation. Brachytherapy 12, 267–277.

  • Smith, B.D., Arthur, D.W., Buchholz, T.A., Haffty, B.G., Hahn, C.A., Hardenbergh, P.H., Julian, T.B., Marks, L.B., Todor, D.A.,

Vicini, F.A., et al. (2009). Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int. J. Radiat. Oncol. Biol. Phys. 74, 987–1001.

Please provide feedback regarding this case or other ARROcases to arrocase@gmail.com

November 16, 2015